High-dose pharmaceutical grade biotin (MD1003) in amyotrophic lateral sclerosis: A pilot study. (February 2020)

• Record Type: Journal Article
• Authors: Juntas-Morales, Raul; Pageot, Nicolas; Bendarraz, Abdelkarim; Alphandéry, Sébastien; Sedel, Frédéric; Seigle, Stéphanie; Camu, William
• Is Part Of: EClinicalMedicine. Volume 19(2020)
• Publication Date: 2020-02
• Subjects: ALS -- Amyotrophic lateral sclerosis -- Motor neuron disease -- Motor neurone disease -- MND -- MD1003 -- Biotin -- phase 2; Medicine -- Research -- Periodicals; Medical policy -- Periodicals; Clinical Medicine; Health Policy; Public Health; Medical policy; Medicine -- Research; Periodical; Electronic journals; Periodicals; 613
• DOI: 10.1016/j.eclinm.2019.100254
• Languages: English
• ISSNs: 2589-5370

Abstract

Abstract: Background: Oligodendrocytes (OGs) provide metabolic support to motor neurons (MNs) and are implicated in the pathophysiology of amyotrophic lateral sclerosis (ALS). MD1003, or high-dose Pharmaceutical grade Biotin (hdPB), may improve disability in progressive multiple sclerosis patients via augmentation of OG or MN energy levels. Here, we assessed the safety and efficacy of MD1003 in ALS patients. Methods: This single centre, randomised, double-blind, placebo-controlled trial included patients aged 25–80 years with probable or definite ALS. Patients were assigned (2:1), using a computer-generated randomisation list, to receive oral MD1003 (300 mg/day) or placebo treatment for 24 weeks. The primary outcome, safety, was analysed in all patients who received at least one dose of study drug. This study, registered with ClinicalTrials.gov, NCT03114215, has been completed. Findings: Between June and December 2016, 30 patients were enrolled (MD1003, n = 20; placebo, n = 10). Baseline characteristics were representative of the ALS population. MD1003 and placebo groups were not well balanced at screening, with the MD1003-treated group having a higher rate of ALSFRS-R decline prior to screening versus placebo (-6·0 IQR [-8·5, -5·0] vs. -5·0 IQR [-5·0, -3·0]) and a predominance of ALS with upper limb onset compared to placebo (35% vs. 10%). MD1003 had a favourable safety profile and was well tolerated. The occurrence of adverse events was similar in both groups (60%). Two deaths occurred in the MD1003 group versus 1 in the placebo group. ALSFRS-R median change from baseline to month 6 was not significantly different between the two groups ( p = 0·49); the mean difference between groups was -1·6 (SEM=3·3). Interpretation: MD1003 treatment was safe and well tolerated. It was not possible to establish MD1003 efficacy in this relatively small study. Given the favourable safety profile of MD1003 and an imbalance between treatment groups favouring placebo, additional, larger studies in ALS are warranted. Funding: MedDay Pharmaceuticals.